Navigation Links
Vioxx Not Safe Even For Short Term Use

Canadian researchers have found that Vioxx painkiller manufactured by Merck & Co would result in an increased risk of heart attack within two weeks after patients start taking the drug. // Statistics show that about 60 patients out of 239 elderly patients suffered from heart attacks within six to 13 days after they first started taking Vioxx. The study results are published in the Canadian Medical Association Journal. It was contrary to what Merck had previously told about the drug. It currently faces 11,500 Vioxx lawsuits. The company has been hit with three jury awards totaling $298.3 million, two of which involved short-term use of the painkiller. It is also associated with the death of a man who took the drug for a period of 30 days.

Linda Levesque, assistant professor of epidemiology at Queen's University in Kingston, Ontario said that it is highly dangerous for the first time users and they might suffer an attack in as little as two weeks. Merck is the fourth-biggest U.S. drug maker. It withdrew Vioxx in 2004 when the drug was proved to double the risk of heart attacks and strokes. It has set aside $970 million for legal costs and vows to fight each case rather than settle out of court. `Cases Easier to Win' Attorney Mark Lanier, the attorney for the drug company has already won two out of the three trials. Canadian researchers analyzed health records of 114,000 patients ages 66 and older who were prescribed painkillers, including Vioxx, Celebrex and ibuprofen. The study followed patients for about two and a half years, included 30,200 Vioxx users and 45,000 Celebrex users. Celebrex was not associated with any heart attacks but when patients started taking Vioxx it significantly increased the risk among patients. But it also diminished. But it is thought that the study would play a major role in contributing to making a better decision by the people.


'"/>




Page: 1

Related medicine news :

1. Increased Heart Attack Risk From Celebrex,Vioxx
2. Merck to pay $ 253.5 million to Vioxx victim family
3. Judgment In Favor Of Merck For Vioxx Drug
4. Could Long Tern Vioxx Users Suffer From Heart Attacks?
5. Doctor Grilled In Court For False Report About Vioxx Health Risk
6. Vioxx and Celebrex, now have alternatives
7. Merck in the Dock Due To Vioxx
8. A Stroke of Bad Luck for Vioxx
9. Arcoxia Slammed –Nothing Better Than Vioxx Says FD
10. Bad News for Short People
11. Painkillers Do Not Shorten Dying Patients Lives
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/11/2016)... ... February 11, 2016 , ... “ HEALING MIND : Five ... Managed Mind” (published by Balboa Press) teaches readers how to become their own therapist. ... love, author Janice McDermott, M.Ed., LCSW, offers an understanding of how to heal one’s ...
(Date:2/11/2016)... Jersey (PRWEB) , ... February 11, 2016 , ... Registered ... a free CEU seminar titled, “Stroke Management: Time to Act, Time to Heal” on ... Community in Whippany, N.J. The presenter is Vishal Chedda, president of ANSA Consultants, ...
(Date:2/11/2016)... ... February 11, 2016 , ... Image One USA ... new market, and it’s the buildings of Nashville that will benefit. , “I’ve enjoyed ... to relocate to Nashville, there was no question that I would bring my business ...
(Date:2/11/2016)... ... February 11, 2016 , ... Pediatric cardiovascular surgeons, cardiologists ... by making data on heart procedures public and easily understandable for families and ... Reporting of Pediatric and Congenital Heart Disease Outcomes will bring hundreds of pediatric ...
(Date:2/11/2016)... ... February 11, 2016 , ... veEDIS Clinical Systems, ... with highly adaptable algorithms, has been updated to help Emergency Department physicians and ... consistent with Zikas and a travel history to affected regions, or potential exposure ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 2016 Transformational M&A achieved through NPS ... --> Transformational M&A achieved through NPS and Dyax ... Transformational M&A achieved through NPS and Dyax acquisitions ... for future growth with most robust pipeline in Shire ... future growth with most robust pipeline in Shire , ...
(Date:2/11/2016)... 11, 2016  AbbVie, a global biopharmaceutical company, ... designed to provide financial support for exceptional students ... higher education goals. Fifteen scholars will be selected ... year. The AbbVie Rheumatology Scholarship is currently accepting ... president, corporate social responsibility, brand and communications, AbbVie. ...
(Date:2/11/2016)... Exactus Pharmacy Solutions, a WellCare (NYSE: ... care for those suffering from long-term, life-threatening or ... Specialty Pharmacy Accreditation from URAC, an independent, nonprofit ... care quality through accreditation, education and measurement. ... URAC accreditation process demonstrates a commitment to quality ...
Breaking Medicine Technology: